EDP Sciences logo
Subscriber Authentication Point
Sciengine logo
Search
Menu
All issues Volume 21 (2026) Math. Model. Nat. Phenom., 21 (2026) 16 References
Open Access
Issue
Math. Model. Nat. Phenom.
Volume 21, 2026
Article Number 16
Number of page(s) 42
Section Mathematical physiology and medicine
DOI https://doi.org/10.1051/mmnp/2026010
Published online 22 April 2026
  1. F. Bray, M. Laversanne, H. Sung, J. Ferlay, R.L. Siegel, I. Soerjomataram and A. Jemal, Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74 (2024) 229–263. [Google Scholar]
  2. A. Marusyk, V. Almendro and K. Polyak, Intra-tumour heterogeneity: a looking glass for cancer? Nat. Rev. Cancer 12 (2012) 323–334. [Google Scholar]
  3. C.E. Meacham and S.J. Morrison, Tumour heterogeneity and cancer cell plasticity. Nature 501 (2013) 328–337. [Google Scholar]
  4. H. Sung, J. Ferlay, R.L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal and F. Bray, Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 71 (2021) 209–249. [Google Scholar]
  5. C. Holohan, S. Van Schaeybroeck, D.B. Longley and P.G. Johnston, Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13 (2013) 714–726. [Google Scholar]
  6. S.V. Sharma, D.Y. Lee, B. Li, M.P. Quinlan, F. Takahashi, S. Maheswaran, U. McDermott, N. Azizian, L. Zou, M.A. Fischbach, K.K. Wong, K. Brandstetter, B. Wittner, S. Ramaswamy, M. Classon and J. Settleman, A chromatin- mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141 (2010) 69–80. [CrossRef] [PubMed] [Google Scholar]
  7. Z.-D. Shi, K. Pang, Z.-X. Wu, Y. Dong, L. Hao, J.-X. Qin, W. Wang, Z.-S. Chen and C.-H. Han, Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies. Signal Transduct. Target. Ther. 8 (2023) 113. [Google Scholar]
  8. Y. Tian, X. Wang, C. Wu, J. Qiao, H. Jin and H. Li, A protracted war against cancer drug resistance. Cancer Cell Int. 24 (2024) 326. [Google Scholar]
  9. X. Wang, H. Zhang and X. Chen, Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2 (2019) 141–160. [Google Scholar]
  10. M. Greaves and C.C. Maley, Clonal evolution in cancer. Nature 481 (2012) 306–313. [Google Scholar]
  11. N. McGranahan and C. Swanton, Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 168 (2017) 613–628. [Google Scholar]
  12. S. Turajlic, A. Sottoriva, T. Graham and C. Swanton, Resolving genetic heterogeneity in cancer. Nat. Rev. Genet. 20 (2019) 404–416. [Google Scholar]
  13. P.B. Gupta, C.M. Fillmore, G. Jiang, S.D. Shapira, K. Tao, C. Kuperwasser and E.S. Lander, Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 146 (2011) 633–644. [CrossRef] [PubMed] [Google Scholar]
  14. A. Marusyk, M. Janiszewska and K. Polyak, Intratumor heterogeneity: the rosetta stone of therapy resistance. Cancer Cell 37 (2020) 471–484. [Google Scholar]
  15. G. Aguade-Gorgorio, A.R.A. Anderson and R. Sole, Modeling tumors as complex ecosystems. iScience 27 (2024) 110699. [Google Scholar]
  16. D. Bilder, K. Ong, T.C. Hsi, K. Adiga and J. Kim, Tumour—host interactions through the lens of Drosophila. Nat. Rev. Cancer 21 (2021) 687–700. [Google Scholar]
  17. R. Brady and H. Enderling, Mathematical models of cancer: when to predict novel therapies, and when not to. Bull. Math. Biol. 81 (2019) 3722–3731. [Google Scholar]
  18. J.S. Brown, S.R. Amend, R.H. Austin, R.A. Gatenby, E.U. Hammarlund and K.J. Pienta, Updating the definition of cancer. Mol. Cancer Res. 21 (2023) 1142–1147. [Google Scholar]
  19. A. Bukkuri, K.J. Pienta, I. Hockett, R.H. Austin, E.U. Hammarlund, S.R. Amend and J.S. Brown, Modeling cancer's ecological and evolutionary dynamics. Med. Oncol. 40 (2023) 109. [Google Scholar]
  20. R.A. Gatenby, A change of strategy in the war on cancer. Nature 459 (2009) 508–509. [Google Scholar]
  21. R.A. Gatenby, A.S. Silva, R.J. Gillies and B. Roy Frieden, Adaptive therapy. Cancer Res. 69 (2009) 4894–4903. [Google Scholar]
  22. M.E. Hochberg, An ecosystem framework for understanding and treating disease. Evol. Med. Public Health (2018) 270–286. [Google Scholar]
  23. N. Zahir, R. Sun, D. Gallahan, R.A. Gatenby and C. Curtis, Characterizing the ecological and evolutionary dynamics of cancer. Nat. Genet. 52 (2020) 759–767. [Google Scholar]
  24. C. Stephan-Otto Attolini and F. Michor, Evolutionary Theory of Cancer. Ann. N. Y. Acad. Sci. 1168 (2009) 23–51. [Google Scholar]
  25. N. Vasan, J. Baselga and D.M. Hyman, A view on drug resistance in cancer. Nature 575 (2019) 299–309. [Google Scholar]
  26. M. Pressley, M. Salvioli, D.B. Lewis, C.L. Richards, J.S. Brown and K. Stanková, Evolutionary dynamics of treatment-induced resistance in canceR informs understanding of rapid evolution in natural systems. Front. Ecol. Evol. 9 (2021) 1–22. [Google Scholar]
  27. J. Zhang, J. Cunningham, J. Brown and R. Gatenby, Evolution-based mathematical models significantly prolong response to abiraterone in metastatic castrate-resistant prostate cancer and identify strategies to further improve outcomes. eLife 11 (2022) 1–105. [Google Scholar]
  28. C. Athena Aktipis, A.M. Boddy, G. Jansen, U. Hibner, M.E. Hochberg, C.C. Maley, G.S. Wilkinson, C. Athena Aktipis, A.M. Boddy, G. Jansen, U. Hibner, M.E. Hochberg, C.C. Maley and G.S. Wilkinson, Cancer across the tree of life: cooperation and cheating in multicellularity. Philos. Trans. Roy. Soc. B: Biol. Sci. 370 (2015) 20140219. [Google Scholar]
  29. P.M. Enriquez-Navas, Y. Kam, T. Das, S. Hassan, A. Silva, P. Foroutan, E. Ruiz, G. Martinez, S. Minton, R.J. Gillies and R.A. Gatenby, Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer. Sci. Transl. Med. 8 (2016). [Google Scholar]
  30. C.C. Maley, A. Aktipis, T.A. Graham, A. Sottoriva, A.M. Boddy, M. Janiszewska, A.S. Silva, M. Gerlinger, Y. Yuan, K.J. Pienta, K.S. Anderson, R. Gatenby, C. Swanton, D. Posada, C.-I. Wu, J.D. Schiffman, E. Shelley Hwang, K. Polyak, A.R.A. Anderson, J.S. Brown, M. Greaves and D. Shibata, Classifying the evolutionary and ecological features of neoplasms. Nat. Rev. Cancer 17 (2017) 605–619. [Google Scholar]
  31. J. West, F. Adler, J. Gallaher, M. Strobl, R. Brady-Nicholls, J. Brown, M. Roberson-Tessi, E. Kim, R. Noble, Y. Viossat, D. Basanta and A.R.A. Anderson, A survey of open questions in adaptive therapy: bridging mathematics and clinical translation. eLife 12 (2023) 1–25. [Google Scholar]
  32. J.A. Gallaher, P.M. Enriquez-Navas, K.A. Luddy, R.A. Gatenby and A.R.A. Anderson, Spatial heterogeneity and evolutionary dynamics modulate time to recurrence in continuous and adaptive cancer therapies. Cancer Res. 78 (2018) 2127–2139. [Google Scholar]
  33. J. West, L. You, J. Zhang, R.A. Gatenby, J.S. Brown, P.K. Newton and A.R.A. Anderson, Towards multidrug adaptive therapy. Cancer Res. 80 (2020) 1578–1589. [Google Scholar]
  34. P.M. Enriquez-Navas, J.W. Wojtkowiak and R.A. Gatenby, Application of evolutionary principles to cancer therapy. Cancer Res. 75 (2015) 4675–4680. [Google Scholar]
  35. C. McGehee and Y. Mori, A mathematical framework for comparison of intermittent versus continuous adaptive chemotherapy dosing in cancer. npj Syst. Biol. Appl. 10 (2024) 140. [Google Scholar]
  36. M.A.R. Strobl, J. Gallaher, M. Robertson-Tessi, J. West and A.R.A. Anderson, Treatment of evolving cancers will require dynamic decision support. Ann. Oncol. 34 (2023) 867–884. [Google Scholar]
  37. J. Zhang, J.J. Cunningham, J.S. Brown and R.A. Gatenby, Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer. Nat. Commun. 8 (2017) 1–9. [Google Scholar]
  38. B. Liu, H. Zhou, L. Tan, K. To Hugo Siu and X.-Y. Guan, Exploring treatment options in cancer: tumor treatment strategies. Signal Transduct. Target. Ther. 9 (2024) 175. [Google Scholar]
  39. M.A.R. Strobl, A.L. Martin, J. West, J. Gallaher, M. Robertson-Tessi, R. Gatenby, R. Wenham, P.K. Maini, M. Damaghi and A.R.A. Anderson, To modulate or to skip: Fe-escalating PARP inhibitor maintenance therapy in ovarian cancer using adaptive therapy. Cell Syst. 15 (2024) 510–525. [Google Scholar]
  40. R.Z. Tan, Tumour Growth Mechanisms Determine Effectiveness of Adaptive Therapy in Glandular Tumours. Interdiscipl. Sci. Computat. Life Sci. 16 (2024) 73–90. [Google Scholar]
  41. M.Y. Wang, J.G. Scott and A. Vladimirsky, Threshold-awareness in adaptive cancer therapy. PLoS Computat. Biol. 20 (2024) e1012165. [Google Scholar]
  42. R.A. Beckman, I. Kareva and F.R. Adler, How should cancer models be constructed? Cancer Control 27 (2020) 1–12. [Google Scholar]
  43. K. Gallagher, M.A.R. Strobl, D.S. Park, F.C. Spoendlin, R.A. Gatenby, P.K. Maini and A.R.A. Anderson, Mathematical model-driven deep learning enables personalized adaptive therapy. Cancer Res. 84 (2024) 1929–1941. [Google Scholar]
  44. R.A. Gatenby and T.L. Vincent, Application of quantitative models from population biology and evolutionary game theory to tumor therapeutic strategies. Mol. Cancer Ther. 2 (2003) 919–927. [Google Scholar]
  45. D. Mathur, E. Barnett, H.I. Scher and J.B. Xavier, Optimizing the future: how mathematical models inform treatment schedules for cancer. Trends Cancer 8 (2022) 506–516. [Google Scholar]
  46. M.A.R. Strobl, J. West, Y. Viossat, M. Damaghi, M. Robertson-Tessi, J.S. Brown, R.A. Gatenby, P.K. Maini and A.R.A. Anderson, Turnover modulates the need for a cost of resistance in adaptive therapy. Cancer Res. 81 (2021) 1135–1147. [Google Scholar]
  47. Y. Deng, L. Xia, J. Zhang, S. Deng, M. Wang, S. Wei, K. Li@, H. Lai, Y. Yang, Y. Bai, Y. Liu, L. Luo, Z. Yang, Y. Chen, R. Kang, F. Gan, Q. Pu@, J. Mei, L. Ma@, F. Lin, C. Guo, H. Liao, Y. Zhu, Z. Liu, C. Liu, Y. Hu@, Y. Yuan, Z. Zha, G. Yuan, G. Zhang, L. Chen, Q. Cheng, S. Shen and L. Liu, Multicellular ecotypes shape progression of lung adenocarcinoma from ground-glass opacity toward advanced stages. Cell Rep. Med. (2024) 101489. [Google Scholar]
  48. L. Ermini, S. Taurone, A. Greco and M. Artico, Cancer progression: a single cell perspective. Eur. Rev. Med. Pharmacol. Sci. 27 (2023) 5721–5747. [Google Scholar]
  49. E. Pennisi, Is cancer a breakdown of multicellularity? Science 360 (2018) 1391–1391. [Google Scholar]
  50. G. Aguade-Gorgorio and S. Kefi, Alternative cliques of coexisting species in complex ecosystems. J. Phys. Complex. 5 (2024). [Google Scholar]
  51. A. Chapman, L.F. del Ama, J. Ferguson, J. Kamarashev, C. Wellbrock and A. Hurlstone, Heterogeneous tumor subpopulations cooperate to drive invasion. Cell Rep. 8 (2014) 688–695. [Google Scholar]
  52. R. Emond, J.I. Griffiths, V.K. Grolmusz, A. Nath, J. Chen, E.F. Medina, R.S. Sousa, T. Synold, F.R. Adler and A.H. Bild, Cell facilitation promotes growth and survival under drug pressure in breast cancer. Nat. Commun. 14 (2023) 3851. [Google Scholar]
  53. M.A. Masud, J.-Y. Kim, C.-H. Pan and E. Kim, The impact of the spatial heterogeneity of resistant cells and fibroblasts on treatment response. PLoS Computai. Biol. 18 (2022) e1009919. [Google Scholar]
  54. M. Robertson-Tessi, B. Desai, T. Miti, P. Kumar, S. Yarlagadda, R. Shah, R.V. Velde, D. Miroshnychenko, D. Basanta, A. Anderson and A. Marusyk, Abstract B008: Therapy-protective peristromal niches mediate positive ecological interaction between therapy-sensitive and therapy-resistant cells, altering the evolutionary dynamics of acquired targeted therapy resistance in lung cancers. Cancer Res. 84 (2024) B008-B008. [Google Scholar]
  55. S. Seyedi, R. Teo, L. Foster, D. Saha, L. Mina, D. Northfelt, K.S. Anderson, D. Shibata, R. Gatenby, L.H. Cisneros, B. Troan, A.R.A. Anderson and C.C. Maley, Testing adaptive therapy protocols using gemcitabine and capecitabine in a preclinical model of endocrine-resistant breast cancer. Cancers 16 (2024) 257. [Google Scholar]
  56. I. Smalley, E. Kim, J. Li, P. Spence, C.J. Wyatt, Z. Eroglu, V.K. Sondak, J.L. Messina, N.A. Babacan, S.S. Maria-Engler, L. De Armas, S.L. Williams, R.A. Gatenby, Y. Ann Chen, A.R.A. Anderson and K.S.M. Smalley, Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma. EBioMedicine 48 (2019) 178–190. [Google Scholar]
  57. C. Grassberger, D. McClatchy, C. Geng, S.C. Kamran, F. Fintelmann, Y.E. Maruvka, Z. Piotrowska, H. Willers, L.V. Sequist, A.N. Hata and H. Paganetti, Patient-specific tumor growth trajectories determine persistent and resistant cancer cell populations during treatment with targeted therapies. Cancer Res. 79 (2019) 3776–3788. [Google Scholar]
  58. E.D. Sunassee, D. Tan, N. Ji, R. Brady, E.G. Moros, J.J. Caudell, S. Yartsev and H. Enderling, Proliferation saturation index in an adaptive Bayesian approach to predict patient-specific radiotherapy responses. Int. J. Radiat. Biol. 95 (2019) 1421–1426. [Google Scholar]
  59. J.B. West, M.N. Dinh, J.S. Brown, J. Zhang, A.R. Anderson and R.A. Gatenby, Multidrug cancer therapy in metastatic castrate-resistant prostate cancer: an evolution-based strategy. Clin. Cancer Res. 25 (2019) 4413–4421. [Google Scholar]
  60. R. Simon and L. Norton, The Norton-—Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens. Nat. Clin. Pract. Oncol. 3 (2006) 406–407. [Google Scholar]
  61. T.A. Traina and L. Norton, Norton-Simon hypothesis, in Encyclopedia of Cancer. Springer Berlin Heidelberg, Berlin, Heidelberg (2011) 2557–2559. [Google Scholar]
  62. Y. Viossat and R. Noble, A theoretical analysis of tumour containment. Nat. Ecol. Evol. 5 (6) 826–835. [Google Scholar]
  63. E. Hansen and A.F. Read, Modifying adaptive therapy to enhance competitive suppression. Cancers 12 (2020) 3556. [Google Scholar]
  64. R. Gatenby and J. Brown, The evolution and ecology of resistance in cancer therapy. Cold Spring Harbor Perspect. Med. 8 (2018). [Google Scholar]
  65. J. Park and P.K. Newton, Stochastic competitive release and adaptive chemotherapy. Phys. Rev. E 108 (2023) 034407. [Google Scholar]
  66. T.M. Parker, K. Gupta, A.M. Palma, M. Yekelchyk, P.B. Fisher, S.R. Grossman, K.J. Won, E. Madan, E. Moreno and R. Gogna, Cell competition in intratumoral and tumor microenvironment interactions. EMBO J. 40 (2021) 1–15. [Google Scholar]
  67. T. Wang and X. Zou, Dynamic analysis of a drug resistance evolution model with nonlinear immune response. Math. Biosci. 374 (2024) 109239. [Google Scholar]
  68. B. Tang, Y. Xiao and J. Wu, Dynamic behaviors of a periodic system with threshold policy-guided periodic and intermittent therapy of tumor. SIAM J. Appl. Math. 85 (2025) 366–392. [Google Scholar]
  69. D. Wang and J. Lei, Optimal adaptive therapeutic schedules for metastatic castrate-resistant prostate cancer based on bilevel optimization problem. J. Math. Biol. 90 (2025) 60. [Google Scholar]
  70. Y. Zhang, T. Vu, D.C. Palmer, R.J. Kishton, L. Gong, J. Huang, T. Nguyen, Z. Chen, C. Smith, F. Livák, R. Paul, C.-p. Day, C. Wu, G. Merlino, K. Aldape, X.-y. Guan and P. Jiang, A T cell resilience model associated with response to immunotherapy in multiple tumor types. Nat. Med. 28 (2022) 1421–1431. [Google Scholar]
  71. M. Strobl, A.L. Martin, J. West, J. Gallaher, M. Robertson-Tessi, R. Gatenby, R. Wenham, P. Maini, M. Damaghi and A. Anderson, Adaptive therapy for ovarian cancer: An integrated approach to PARP inhibitor scheduling. bioRxiv (2023). [Google Scholar]
  72. T. Brabletz, R. Kalluri, M.A. Nieto and R.A. Weinberg, EMT in cancer. Nat. Rev. Cancer 18 (2018) 128–134. [Google Scholar]
  73. A. Uthamacumaran and H. Zenil, A review of mathematical and computational methods in cancer dynamics. Front. Oncol. 12 (2022) 1–26. [Google Scholar]
  74. F.-S. Wang and C. Zhang, What to do next to control the 2019-nCoV epidemic? Lancet 395 (2022) 391–393. [Google Scholar]
  75. R. Noble, D. Burri, C. Le Sueur, J. Lemant, Y. Viossat, J. N. Kather and N. Beerenwinkel. Spatial structure governs the mode of tumour evolution. Nat. Ecol. Evol. 6 (2021) 207–217. [Google Scholar]
  76. T. Lorenzi, R.H. Chisholm and J. Clairambault, Tracking the evolution of cancer cell populations through the mathematical lens of phenotype-structured equations. Biol. Direct 11 (2016) 43. [PubMed] [Google Scholar]
  77. J. West, Y. Ma and P.K. Newton, Capitalizing on competition: an evolutionary model of competitive release in metastatic castration resistant prostate cancer treatment. J. Theoret. Biol. 455 (2018) 249–260. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.